Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AR-17043 · 1 trial · 2 indications
Intraocular pressure (IOP) will be measured with a Goldmann tonometer. Diurnal IOP will be calculated as the average of the four measurements.
Intraocular pressure (IOP) will be measured with a Goldmann tonometer. Diurnal IOP will be calculated as the average of the three measurements.
| Arm | Type | Description |
|---|---|---|
| AR-17043 low concentration (Stage 1) | EXPERIMENTAL | AR-17043 Ophthalmic Solution, one drop in each eye in the morning on Day 1, followed by one drop in each eye in the evening on Days 2-7. |
| AR-17043 medium concentration (Stage 1) | EXPERIMENTAL | AR-17043 Ophthalmic Solution, one drop in each eye in the morning on Day 1, followed by one drop in each eye in the evening on Days 2-7. |
| AR-17043 high concentration (Stage 1) | EXPERIMENTAL | AR-17043 Ophthalmic Solution, one drop in each eye in the morning on Day 1, followed by one drop in each eye in the evening on Days 2-7. |
| AR-17043 vehicle (Stage 1) | PLACEBO_COMPARATOR | AR-17043 Vehicle, one drop in each eye in the morning on Day 1, followed by one drop in each eye in the evening on Days 2-7. |
| Rhopressa (Stage 1) | ACTIVE_COMPARATOR | Netarsudil 0.02% Ophthalmic Solution, one drop in each eye in the morning on Day 1, followed by one drop in each eye in the evening on Days 2-7. |
| PG043 low concentration (Stage 2) | EXPERIMENTAL | PG043 Ophthalmic Solution, one drop in each eye in the evening on Days 1-28. |
| PG043 high concentration (Stage 2) | EXPERIMENTAL | PG043 Ophthalmic Solution, one drop in each eye in the evening on Days 1-28. |
| AR-17043 high concentration (Stage 2) | ACTIVE_COMPARATOR | AR-17043 Ophthalmic Solution, one drop in each eye in the evening on Days 1-28. |
| Latanoprost (Stage 2) | ACTIVE_COMPARATOR | Latanoprost 0.005% Ophthalmic Solution, one drop in each eye in the evening on Days 1-28. |
| Rocklatan (Stage 2) | ACTIVE_COMPARATOR | Netarsudil 0.02%/Latanoprost 0.005% Ophthalmic Solution, one drop in each eye in the evening on Days 1-28. |
| Name | Type | Description |
|---|---|---|
| AR-17043 Ophthalmic Solution | DRUG | Investigational monotherapy supplied in three concentration levels: low, medium, high |
| PG043 Ophthalmic Solution | DRUG | Investigational fixed dose combination supplied in two concentration levels: low and high |
| Latanoprost 0.005% Ophthalmic Solution | DRUG | Marketed monotherapy |
| Netarsudil 0.02% Ophthalmic Solution | DRUG | Marketed monotherapy |
| Netarsudil 0.02%/Latanoprost 0.005% Ophthalmic Solution | DRUG | Marketed fixed dose combination |
| AR-17043 Vehicle | DRUG | Placebo comparator |
Stage 1 Key Inclusion Criteria; * Diagnosis of OAG or OHT in both eyes. * High unmedicated IOP measurements in the study eye as specified in the protocol. * Corrected visual acuity equal to or better than +1.0 logMAR (Snellen equivalent equal to or better than 20/200) in the study eye. * Other prot...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Glaukos Corp | GKOS | 3 | PHASE4 | Travoprost Intraocular |
| Amneal Pharmaceuticals, Inc. Class A | AMRX | 1 | PHASE4 | Test - Bimatoprost 0.01%, Reference - LUMIGAN |
| AbbVie, Inc. | ABBV | 1 | PHASE4 | Bimatoprost |
| United Therapeutics Corporation | UTHR | 1 | PHASE4 | Nicotinomide |
| Alcon AG | ALC | 3 | PHASE4 | Undisclosed |
AR-17043 is an investigational small molecule being developed for the treatment of open angle glaucoma and ocular hypertension. It is currently in Phase 2 clinical development.
AR-17043 is being developed by Alcon Inc. (NYSE: ALC), a pharmaceutical company focused on eye care.
AR-17043 is in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities.
AR-17043 has completed one Phase 2 clinical trial, NCT06441643, which enrolled 426 participants with open angle glaucoma and ocular hypertension. The trial was a randomized, double-blind, placebo-controlled study conducted in the United States.
AR-17043 is also known as Next Generation Rocklatan, as referenced in the clinical trial NCT06441643. It is being studied for the treatment of open angle glaucoma and ocular hypertension.